{"store":{"baseInfo":{"podcastTitle":"Curbside Consults","slug":"nejm-resident-360-curbside-consults","podcastDescription":"This podcast from NEJM Resident 360 takes a deep dive into key topics with expert clinicians and educators. As we explore the details of pathophysiology and critique the evidence behind clinical practice, these conversations are intended to give you better understanding of the topic and greater confidence when treating your patients.","podcastLogo":"https://pbcdn1.podbean.com/imglogo/image-logo/14794373/NEJM_Res360_Curbside_RGB-3000-255k_2gsq7z.jpg","podcastShareLogo":"https://d2bwo9zemjwxh5.cloudfront.net/image-logo/14794373/NEJM_Res360_Curbside_RGB-3000-255k_2gsq7z_1200x628.jpg?s=b29246ac37fbdd963f405e6e78862224&e=jpg","podcastUrl":"https://resident360-curbside-consults.nejm.org","podcastCanSearched":true,"feedUrl":"https://resident360-curbside-consults.nejm.org/feed.xml","theme":"elegant","podcastDeepLink":"https://www.podbean.com/pu/pbblog-xpbaq-e1be85","removePodbeanBranding":"yes","brandingLogo":null,"timeZone":{"timeZoneId":15,"gmtAdjustment":"GMT-05:00","useDaylightTime":1,"value":-5,"text":"(GMT-05:00) Eastern Time (US & Canada)","daylightStartTime":"Second Sunday Of March +2 Hours","daylightEndTime":"First Sunday Of November +2 Hours","timezone":"America/New_York"},"podcastDownloads":null,"totalEpisodes":76,"showComments":false,"iOSAppDownloadLink":null,"customizeCssUrl":null,"androidAppDownloadLink":null,"showPostShare":false,"showLike":false,"author":"NEJM Group","engagementStatsBaseUrl":"https://d1.podbean.com/webplayer_engagement?u=673fa84f4cc1026d0e09118c","shareEmbedLink":"https://admin5.podbean.com/embed.html?id=pbblog-xpbaq-e1be85-playlist","language":"en","sensitivitySessionExpireTime":3600,"podcastApps":[{"name":"Podbean App","link":"https://r4j68.app.goo.gl/?link=https%3A%2F%2Fresident360-curbside-consults.nejm.org%3Faction%3DopenPodcast%26podcastId%3Dpbblog14794373%26podcastIdTag%3Dxpbaq&dfl=https%3A%2F%2Fresident360-curbside-consults.nejm.org&utm_campaign=pb_web&utm_source=podbean_web&utm_medium=dlink&imv=670&amv=530&isi=973361050&ibi=com.podbean.app.podcast&ipbi=com.podbean.app.podcast&apn=com.podbean.app.podcast","image":"https://pbcdn1.podbean.com/fs1/site/images/admin5/podbean-app.png","title":null}],"components":{"base":[{"id":"MainStyle","val":"light"},{"id":"Font","val":"Avenir"},{"id":"SecondaryFont","val":"Avenir"},{"id":"PlayerColor","val":"#8fc31f"},{"id":"PlayerStyle","val":"player1"},{"id":"PlayerWave","val":"show"},{"id":"Favicon","val":null},{"id":"CookiesNotice","val":"hide"},{"id":"CookiesNoticeContent","val":"

Cookies Notice

This website uses cookies to improve your experience while you navigate through the website. By using our website you agree to our use of cookies.

"}],"home-header":[{"id":"HomeHeaderTextColor","val":"#000000"},{"id":"HomeHeaderBackgroundColor","val":"#ffffff"}],"page-header":[{"id":"PageHeaderTextColor","val":"#ffffff"},{"id":"PageHeaderBackgroundColor","val":"#868686"}],"episode-list":[{"id":"EpisodeListType","val":"grid"},{"id":"EpisodesPerPage","val":10},{"id":"EpisodeStats","val":"show"}],"navigation":[{"id":"NavigationFontColor","val":"#000000"},{"id":"NavigationBackgroundColor","val":"#009999"},{"id":"NavigationSearch","val":"show"},{"id":"NavigationLinks","val":[{"id":"Home","type":"Link","value":"/","text":"Home","subitems":[]}]}],"footer":[{"id":"FooterType","val":"Footer2"},{"id":"FooterFontColor","val":"#ffffff"},{"id":"FooterBackgroundColor","val":"#000000"},{"id":"FooterCopyright","val":"Copyright {year} All rights reserved."},{"id":"SocialMediaLinks","val":{"facebook_username":"TheNewEnglandJournalofMedicine","twitter_username":"NEJM","instagram_username":"nejm","youtube_username":"nejmgroup","linkedin_username":""}}],"customize-container1":[],"customize-container2":[{"id":"ComponentImageText-1","val":{"ComponentFontColor":"#000000","ComponentBackgroundColor":"#f2f2f2","ComponentImage":"https://mcdn.podbean.com/mf/web/nhrx88/new-res360-nephrology-laptop.png","ComponentContent":"

About NEJM Resident 360

Designed specifically for medical residents, NEJM Resident 360 gives you the information, resources, and support you need to approach your clinical rotations — and life as a resident — with confidence. NEJM Group editorial staff, fellows, and specialists curate the most trustworthy and important content from The New England Journal of Medicine and other respected journals.

For more resources or to sign up, visit
https://resident360.nejm.org

"}}]},"allLinks":[],"mainStylesDefaultSettings":null,"defaultCustomizeComponents":null,"scripts":[],"metas":null,"appConfig":{"package":"com.podbean.app.generic","app_store_id":1484287462,"app_name":"Podbean Biz Podcast App","scheme":"enterprise-podbean-com"},"customizeCss":null,"canEditCss":null,"enableJsCodeInCustomizeContent":false,"enabledIframeCodeInCustomizeContent":true,"sectionMaxCount":10,"enableEditorLink":true,"enableEditCookiesNotice":true,"siteRedirectToFeed":false,"podcatcherRssUrl":null,"showFeed":true,"showTopBar":true,"enableWebSiteLike":false,"organizationName":"NEJM Group","organizationPageLink":"https://www.podbean.com/podcast-network/nejmgroup"},"backToListUrl":"/","tinymceLoaded":false,"listEpisodes":[],"userLikedEpisodes":[],"topBarIframeLoaded":false,"listTotalCount":0,"listTotalPage":0,"listPage":0,"listType":"all","listValue":"","listName":"","pageLoading":false,"apiBaseUrl":"http://resident360-curbside-consults.nejm.org","apiCommonParams":{"t":"673fa84f","clientSignature":"ce8e5dc66f8bfdfc0da68e401f032355","u":null,"customizing":null},"apiCommonHeaders":{},"comments":[],"commentsTotalCount":null,"commentsTotalPage":null,"commentsPage":null,"commentEpisodeId":null,"episode":{"id":"pb19464426","idTag":"p9ktn","title":"Rivaroxaban for Reducing Vascular Event Risks after Limb Revascularization for Peripheral Artery Disease – The VOYAGER PAD Trial with Dr. Marc Bonaca","logo":"https://pbcdn1.podbean.com/imglogo/image-logo/14794373/NEJM_Res360_Curbside_RGB-3000-255k_2gsq7z_300x300.jpg","shareLogo":"https://d2bwo9zemjwxh5.cloudfront.net/image-logo/14794373/NEJM_Res360_Curbside_RGB-3000-255k_2gsq7z_1200x628.jpg?s=b29246ac37fbdd963f405e6e78862224&e=jpg","largeLogo":"https://pbcdn1.podbean.com/imglogo/image-logo/14794373/NEJM_Res360_Curbside_RGB-3000-255k_2gsq7z.jpg","previewContent":null,"content":"In today’s podcast we are joined by Dr. Marc Bonaca to discuss the findings of the recent VOYAGER PAD trial and the use of low-dose rivaroxaban in peripheral artery disease after revascularization.","publishTimestamp":1590753420,"duration":2027,"mediaUrl":"https://mcdn.podbean.com/mf/web/omq0lj/video_authenticated_s--8_mPsgZB--_v1590752654_NEJMr360CurbsideConsults_034_Bonanca.mp3","mediaType":"audio/mpeg","shareLink":"https://admin5.podbean.com/embed.html?id=pb-p9ktn-12900ea","likedCount":0,"deepLink":"https://www.podbean.com/ew/pb-p9ktn-12900ea","transcriptUrl":"https://mcdn.podbean.com/mf/web/k4hwhz/video_authenticated_s--8_mPsgZB--_v1590752654_NEJM_hzpzqe.srt","permalink":"/e/rivaroxaban-forreducingvascular-eventrisksafter-limb-revascularizationfor-peripheralartery-disease%e2%80%93-thevoyager-pad-trial-with-dr-marc-bonaca/","downloadLink":null,"fallbackResource":null,"fallbackResourceMimetype":null,"downloadCount":0,"status":"publish","hasMoreContent":false,"chaptersUrl":null},"episodeShareLink":null,"deepLink":"https://www.podbean.com/ew/pb-p9ktn-12900ea","playlist":{"episodes":[],"current":0,"start":0,"stop":0,"playing":true,"playerLoading":true,"playbackRate":1,"playbackRateIndex":1},"toasts":[],"confirm":null,"customizeEditorFormZIndex":999,"lastRequestTime":null,"validateChangesOnBeforeunload":true,"windowWidth":1000,"VITE_FS1_CDN_URL_PREFIX":"https://pbcdn1.podbean.com/fs1","reloadStats":false},"episode":{"id":"pb19464426","idTag":"p9ktn","title":"Rivaroxaban for Reducing Vascular Event Risks after Limb Revascularization for Peripheral Artery Disease – The VOYAGER PAD Trial with Dr. Marc Bonaca","logo":"https://pbcdn1.podbean.com/imglogo/image-logo/14794373/NEJM_Res360_Curbside_RGB-3000-255k_2gsq7z_300x300.jpg","shareLogo":"https://d2bwo9zemjwxh5.cloudfront.net/image-logo/14794373/NEJM_Res360_Curbside_RGB-3000-255k_2gsq7z_1200x628.jpg?s=b29246ac37fbdd963f405e6e78862224&e=jpg","largeLogo":"https://pbcdn1.podbean.com/imglogo/image-logo/14794373/NEJM_Res360_Curbside_RGB-3000-255k_2gsq7z.jpg","previewContent":null,"content":"In today’s podcast we are joined by Dr. Marc Bonaca to discuss the findings of the recent VOYAGER PAD trial and the use of low-dose rivaroxaban in peripheral artery disease after revascularization.","publishTimestamp":1590753420,"duration":2027,"mediaUrl":"https://mcdn.podbean.com/mf/web/omq0lj/video_authenticated_s--8_mPsgZB--_v1590752654_NEJMr360CurbsideConsults_034_Bonanca.mp3","mediaType":"audio/mpeg","shareLink":"https://admin5.podbean.com/embed.html?id=pb-p9ktn-12900ea","likedCount":0,"deepLink":"https://www.podbean.com/ew/pb-p9ktn-12900ea","transcriptUrl":"https://mcdn.podbean.com/mf/web/k4hwhz/video_authenticated_s--8_mPsgZB--_v1590752654_NEJM_hzpzqe.srt","permalink":"/e/rivaroxaban-forreducingvascular-eventrisksafter-limb-revascularizationfor-peripheralartery-disease%e2%80%93-thevoyager-pad-trial-with-dr-marc-bonaca/","downloadLink":null,"fallbackResource":null,"fallbackResourceMimetype":null,"downloadCount":0,"status":"publish","hasMoreContent":false,"chaptersUrl":null},"comments":[],"commentTotalCount":0,"commentTotalPage":0}